Is this your company? Get featured or correct your listing →
Recent changes
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2026 | Series B | $130M | — | Frazier Life SciencesLeadunverified | Pulse story |
Investors
Latest Pulse
- Oct 14, 2026Frazier Life Sciences II Prices $75M IPO, Lists FLSCFrazier Life Sciences Acquisition Corp. II priced its $75M IPO at $10 a share, with shares beginning Nasdaq trading under ticker FLSC on October 14.→
- Jul 22, 2026Crystalys Raises $130M to Push Gout Drug Through Phase 3Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.→
Coverage Timeline
newest firstAll Coverage
Related Companies
Crystalys Therapeutics FAQ
Who are Crystalys Therapeutics's investors?
Crystalys Therapeutics's investors include Frazier Life Sciences.
Sources & methodologyshow
Where these figures come from
- citybizValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.